Brainstorm cell therapeutics regains compliance with nasdaq minimum market value rule

New york , april 11, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli, "the company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "notification letter on compliance") on april 10, 2024 from the listing qualifications department of the nasdaq stock market ("nasdaq"), indicating that the company has regained compliance with the minimum market value of listed securities requirement set forth under nasdaq listing rule 5550(b)(2) (the "rule"). according to the notification letter on compliance, nasdaq's staff has determined that for the 11 consecutive business days, from march 22, 2024 through april 9, 2024, the company's market value of listed securities has been $35,000,000 or greater, and the company has regained compliance with the rule.
BCLI Ratings Summary
BCLI Quant Ranking